Item 5.02 Departure of Directors or Certain Officers; Election of Directors;


          Appointment of Certain Officers; Compensatory Arrangements of Certain
          Officers.

On January 9, 2020, Replimune Group, Inc. (the "Company") issued a press release announcing that, effective as of January 8, 2020 (the "Effective Date"), Dr. Robert Coffin transitioned from the role of Chief Executive Officer to the role of President and Chief Research & Development Officer. In connection with such transition, Mr. Philip Astley-Sparke, the Company's part-time Executive Chairman, replaced Dr. Coffin as the Company's full time Chief Executive Officer.

Pursuant to Mr. Astley-Sparke's current employment arrangement with the Company, Mr. Astley-Sparke devotes 80% of his time working for the Company. The Company expects to proportionately increase Mr. Astley-Sparke's base salary to reflect his transition from part-time Executive Chairman to full-time Chief Executive Officer.

Information regarding Dr. Coffin and Mr. Astley-Sparke required by Items 401(b), (d), (e) and Item 404(a) of Regulation S-K is hereby incorporated by reference to the Company's annual report on Form 10-K filed with the Securities and Exchange Commission (the "SEC") on June 28, 2019, as amended by Amendment No. 1 thereto filed with the SEC on July 29, 2019.

Item 9.01 Financial Statements and Exhibits.






 Exhibit No.   Exhibit Name
  99.1           Replimune Group, Inc. Press Release, dated January 9, 2020

© Edgar Online, source Glimpses